Intersect Ent, Inc. (XENT): Lisa D Earnhardt , President and CEO of Intersect Ent, Inc. sold 28,500 shares on Apr 15, 2016. The Insider selling transaction was reported by the company on Apr 19, 2016 to the Securities and Exchange Commission. The shares were sold at $18.92 per share for a total value of $532,587.81 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 22, 2016, Richard E Kaufman (Sr VP& Chief Operating Officer) sold 3,603 shares at $16.51 per share price.On Mar 16, 2016, Lisa D Earnhardt (President and CEO) sold 9,000 shares at $18.01 per share price.Also, On Jul 21, 2015, James Stambaugh (VP Clinical Affairs) sold 12,000 shares at $30.52 per share price.On May 11, 2015, Amy Wolbeck (V.P. Regulatory Affairs & Qlty) sold 80 shares at $23.10 per share price.
Intersect ENT Inc: On Monday, Apr 18, 2016 heightened volatility was witnessed in Intersect ENT Inc which led to swings in the share price. The shares opened for trading at $18.65 and hit $19.56 on the upside , eventually ending the session at $19.44, with a gain of 4.01% or 0.75 points. The heightened volatility saw the trading volume jump to 1,70,540 shares. The 52-week high of the share price is $32.85 and the company has a market cap of $548 M . The 52-week low of the share price is at $15.6.
Currently the company Insiders own 37.9% of Intersect ENT Inc shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by -3.66%.Institutional Investors own 83.04% of Intersect ENT Inc shares.During last six month period, the net percent change held by insiders has seen a change of -4.38%.
Intersect ENT Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear nose and throat conditions. The Company’s commercial products are the PROPEL and PROPEL mini drug-eluting implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is also developing PROPEL mini for use in frontal sinus surgery and is conducting clinical trials to evaluate two products RESOLVE and NOVA for treatment of patients in the physician’s office. The Company is developing the RESOLVE steroid releasing implant as an alternative treatment option for patients who are candidates for revision surgery that can be placed in the physician office setting during a routine visit. The Company is also developing NOVA a steroid releasing implant designed to fit the openings of the frontal and maxillary sinuses following ostial dilation using balloon sinuplasty.